% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

  • rob_cos rob_cos Apr 11, 2013 10:40 PM Flag

    Roth "FDA decision helps ACAD valuation in 4 ways.....Increasing Target to $20"..

    Roth "FDA decision helps ACAD valuation in 4 ways. Pim to be widely prescribed, incl off-label Alzheimers given clean label - peak sales reaching well over $1 billion...Increasing Target to $20"...

    Full rpt doesnt post on yahoo - this and other full reports on Investorvillage ACAD board

    Roth Capital Partners, LLC

    Estimates Changed, Target Price Increased

    12-Mo.Price Target $20.00

    ACAD: Pimavanserin Development Accelerates

    After meeting with FDA, based on the strength and consistency of the results for pimavanserin in the 020 study, another Phase 3 study is not necessary for its filing for psychosis related to Parkinson's disease. This moves forward pimavanserin's estimated approval to late 2015, and increases the possibility of a takeover of Acadia, given the scarcity of meaningful CNS assets. We reiterate our Buy and raise our ACAD target to $20.

    Important Progress for Pimavanserin: No Additional Phase 3 Needed.

    After a meeting with FDA, Acadia management has determined that based on the strength of the recent Phase 3 results onm study 020 for pimavansein in Parkinson's psychosis, another Phase 3 study is not necessary. This positive and rare occurrence is based on the strength of the therapy's 020 study, which was a large multicenter study, that demonstrated strong, consistent data across a number of metrics.

    Pimavanserin's 020 Study Results Lead to Early Consideration by FDA.

39.20+0.92(+2.40%)Nov 27 1:00 PMEST